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Background and purpose of the study: Considering the role of inflammation in acute cerebrovascular accidents,
anti-inflammatory treatment has been considered as an option in cerebrovascular diseases. Regarding the
properties of Setarud (IMOD™) in immune regulation, the aim of the present study was to evaluate the role of this
medication in treating patients with acute ischemic stroke.
Methods: In this randomized clinical trial, 99 patients with their first ever acute ischemic stroke were divided into
two groups of IMOD™ (n = 49) and control (n = 50). The control group underwent routine treatment and the
intervention group underwent routine treatment plus daily intermittent infusion of IMOD™ (250mg on the first day
and then 375mg into DW5% serum during a 30-minute period for 7 days). The serum levels of inflammatory
markers were evaluated on the first day (baseline) and on 4th and 7th days. Data were analyzed and the results
were compared.
Results and major conclusion: 58 males (58.6%) and 41 females (41.4%) with a mean age of 67.00 ± 8.82 years,
who had their first ever stroke attack, were enrolled in this trial. Treatment with IMOD™ showed a decreasing trend
in IL-6 levels compared to the control group (p = 0.04). In addition, the treatment resulted in the control of
increasing serum levels of hsCRP after 7 days compared to the control group (p = 0.02). There was an insignificant
decrease in TNF-α and IL-1 levels in the IMOD™ group. Considering the prominent role of inflammation after an
ischemic cerebral damage, it appears that treatment with IMOD™ improves the inflammatory profile. Therefore,
IMOD™ (Setarud) might be considered as a therapeutic option in the acute ischemic stroke. However, future studies
are necessary on its long-term results and clinical efficacy.
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Cerebrovascular accident is the main etiologic factor for
disability in adults and the second most important cause
of death worldwide [1]. Based on available evidence, a
strong inflammatory reaction is induced subsequent to
acute CVA, which has a great role in cerebral injury,
demonstrating a significant interaction between the im-
mune and nervous systems [2,3].
This inflammatory reaction is mediated by various cells,
molecules and cytokines [3]; cytokines are upregulated in* Correspondence: mnajafi_md@yahoo.com
1Neuroscience Research Center (NSRC), Imam Reza Hospital, Tabriz University
of Medical Sciences, Tabriz, Iran
Full list of author information is available at the end of the article
© 2013 Farhoudi et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe brain after the stroke and are expressed not only in
the immunologic cells but also in the glial cells and
neurons [4].
The most extensively studied cytokines associated with
stroke are IL-1β, IL-10, IL-6 and TNF-α. IL-1β and TNF-α,
proinflammatory cytokines secreted by the activated im-
mune cells in the ischemic area, induce the inflammatory
process and facilitate the inflammatory cascade by inducing
the expression of inflammatory molecules. These molecules
recruit more leukocytes to the affected ischemic area, give
rise to the loss of more nerve cells, cause cerebral tissue
and expand cerebral infarction [5,6].
Considering the role of cytokines in neurologic inflam-
mation, these inflammatory mediators can be the target ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tory medication is a substance that alters the ability of the
immune system to produce antibodies or sensitized cells
that recognize and react with the antigens that have ini-
tiated their production.
Setarud (IMOD™) is a combination of the extracts of
Tanacetum vulgare, Rosa canina and Urtica dioica plant
species, which has been enriched with selenium. The plant
content of this medication has anti-inflammatory and
immunoregulatory properties and selenium has a protect-
ive effect against oxidative stress. Extracts from Urtica
dioica may prevent maturation of myeloid dendritic cells
and reduce T cell responses. Multiple in vitro and in vivo
studies in animal models and also in human has shown
that it decreases TNF-α, IFN-γ and IL-2 levels and its
effect in some clinical situations, such as experimental in-
flammatory bowel diseases, immunogenic type-1 diabetes
in mouse and also in patients with sepsis and in HIV pa-
tients, has been evaluated due to its immunoregulatory
properties [8-15]. Shirazi and colleagues in an in vitro
study concluded that the dose-dependent inhibitory effect
of Setarud on TLR stimulated B lymphocytes implies its
potential therapeutic implication in B lymphocyte medi-
ated autoimmune diseases and B-cell malignancies [16].
In addition, the herbal content of this medication can ex-
hibit anti-inflammatory, anti-viral and immonomodulatory
effects [17-20].
Considering the inflammatory changes during the acute
phase of ischemic stroke and its central role on disease
outcome, anti-inflammatory treatment might be an appro-
priate option in such patients; in addition, considering the
role of IMOD™ in immunoregulation, the aim of the pre-
sent study was to evaluate the effect of this medication on
chief inflammatory biomarkers in patients with acute is-
chemic cerebrovascular accidents.
Methods
After approval of the ethics committee of Tabriz University
of Medical Sciences, 99 patients with first attack of acute
ischemic stroke (AIS), hospitalized in Tabriz Imam Reza
and Razi Hospitals from September 2011 to March 2012,
were enrolled in the study (using convenient sampling),
and were randomly divided into two groups, with an allo-
cation sequence based on a block size of fifty, generated
with computer random-number generator. Allocation was
concealed by use of sequentially numbered black enve-
lopes. (IRCT No: IRCT 201108202195N2)
The AIS was initially diagnosed using Cincinnati
Prehospital Stroke Scale (Facial droop, Arm drift and
Speech) and confirmed based on clinical criteria and
imaging techniques as used in TOAST Subtype Classifi-
cation System [21]. The exclusion criteria were: age over
80 or under 18; previous history of stroke; a previous
neurological deficit of any cause; cancer or any othersevere disease; a rapid improvement in signs and symp-
toms before the institution of treatment; a baseline
NIHSS (National Institutes of Health Stroke Scale)
below5; elapse of less than 3 hours and more than 24
hours after the appearance of signs and symptoms; re-
fusal to sign an informed consent form and a history of
taking immunomodulatory medications such as immu-
noglobulin’s or steroids.
All the patients who were available during the speci-
fied time interval and had the inclusion criteria were en-
rolled in the study. Since it was not possible to use
placebo because of technical and ethical limitations,
blinding was carried out through masked evaluation and
any unmasked condition was taken into account during
statistical analysis.
In the present study the subjects were divided into two
randomized groups of case and control using stratified
block randomization technique. The subjects in the con-
trol groups underwent a routine treatment protocol
(according to the protocol of the University Department
of Neurology); the subjects in the case group underwent
routine treatment protocol plus daily intermittent infusion
of IMOD™ (250mg on the first day and 375mg on the
subsequent days into DW5% serum) during 30 minutes
for 7 days. Previous studies showed that IMOD didn’t
have any side effect and only one case of phlebitis was
reported [9]. So we used DW5% for its dilution and a dur-
ation of 30 minutes time for IMOD injection to reduce
the probability of phlebitis. Both groups equally received
routine therapeutic, supportive and rehabilitative mea-
sures. All study participants had blood samples taken at
the first, fourth and seventh day of admission. Non-fasting
blood was collected and within 30 minutes, the blood was
centrifuged for 15 minutes at 3000 rotations per minute at
room temperature. Subsequently, U-CyTech kit was used
for determination of serum inflammatory markers by
ELISA method. The levels of TNF-α, IL-6 and IL-1, and
also platelets, WBC and High-sensitive CRP were deter-
mined on the first day of disease presentation (before
treatment) and on the 4th and 7th days, by laboratory pro-
cedures in the hospital immunology department.
Informed consent was obtained from all the subjects.
All the subjects were thoroughly under supervision in
relation to the occurrence of any complication and all
the equipment necessary for the control of acute condi-
tions were available in the department.
Statistical analysis
STATA 11W statistical software was used to provide a
randomization list in two equal 50-member blocks. Data
were analyzed using SPSS 16W statistical software.
Independent t-test, or as required Mann–Whitney U test,
was used for quantitative variables. Repeated measures
ANOVA were used to evaluate changes in quantitative
Table 2 Baseline clinical characteristics based on NIHSS in
the two groups under study
IMOD™ group Control group P value
NIHSS 10.59 ± 5.56 11.04 ± 6.56 0.71
Facial weakness 1.57 ± 0.54 1.50 ± 0.54 0.51
Arm weakness 2.33 ± 1.12 2.30 ± 1.24 0.91
Leg weakness 2.02 ± 1.14 1.96 ± 1.27 0.80
Speech difficulty 1.33 ± 0.47 1.36 ± 0.56 0.75
NIHSS: National Institute of Health Stroke Scale.
Data are mean ± SE.
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defined at P < 0.05.
Results
In the present study, 99 patients with their first ever stroke
consisting of 58 males (58.6%) and 41 females (41.4%)
with a mean age of 67.00 ± 8.82 years, were enrolled.
Forty-nine patients (49.5%) were randomly placed in the
IMOD™ group and 50 patients (50.5%) were placed in the
control group. Tables 1 and 2 presents the baseline data of
the two groups. As it is shown the two groups were
matched in relation to all the baseline findings.
The mean duration of time between the appearance of
signs and symptoms and the institution of treatment was
12.92 ± 3.80 hours in the IMOD™ group, with a median of
13 hours. The shortest and longest times were 5 and 21
hours, respectively. The patients in the IMOD™ group
were aware, lethargic, obtunded and stuporous in 85.7%,
8.20%, 2% and 4.10% of cases, respectively at the time of
referral; the percentages above were 70%, 16%, 4% and 6%,
respectively, in the control group, with 4% of comatose
patients in this group. In relation to stroke types in the
TOAST classification [21], in the IMOD™ group the ves-
sel involvements were as follows: 26 cases (53.1%) of large
vessels, 5 cases (10.2%) of cardioembolic and 18 cases
(36.7%) of lacunar; in the control group the percentages
above were as follows, respectively: 26 cases (52%), 6 cases
(12%) and 18 cases (36%). No significant differences were
observed between the two groups (p = 0.93).No major ad-
verse effect of IMOD injection was seen except for three
cases of superficial phlebitis that resolved by conservative
measures.Table 1 Baseline findings in the two groups under study
IMOD™ group Control group P value
Age 67.00 ± 8.16 67.00 ± 9.50 0.90
Gender (male) 30 (61.2%) 28 (56.0%) 0.68
IHD 15(30.6%) 13 (26.0%) 0.66
HTN 38(77.6%) 35 (70.0%) 0.49
DM 6(12.2%) 10(20.0%) 0.41
CHF 1(2.0%) 2(4.0%) 0.90
Smoking 9(18.4%) 15(30.0%) 0.24
Atrial Fibrillation 3(6.1%) 4(8.0%) 0.9
Hyperlipidemia 7(14.3%) 13(26.0%) 0.21
ASA use 18(36.7%) 20(40.0%) 0.77
ACEI/ARB use 28(57.1%) 26(52.0%) 0.72
Statin use 7(14.3%) 13(26.0%) 0.21
DM: Diabetes Mellitus, CHF: Congestive Heart Failure, IHD: Ischemic Heart
Failure, HTN: Hypertension.
ACEI/ARB: Angiotensin Converting Enzyme Inhibitors/Angiotensin
Receptor Blockers.
Data are mean ± SE.Considering the differences in the laboratory findings
between the two groups (insignificant at baseline), the
effects of the medications were evaluated by assessing
the changes observed.
Figure 1 shows changes in IL-1 levels in the two groups
during the study. As the figure shows IL-1 exhibited a de-
creasing trend in the IMOD™ group; however, it exhibited
almost constant variations in the control group. No sig-
nificant differences were observed between the two groups
(p = 0.20).
As shown in Figure 1, IL-6 levels increased significantly
in the control group until the 7th day. However, treatment
successfully decreased the levels of this marker (p = 0.04).
Figure 1 also shows changes in TNF-α level in the two
groups; TNF-α levels exhibited a mild increase in the
control group by the 7th day but decreased in the
IMOD™ group; however, treatment did not significantly
decrease TNF-α levels (p = 0.10).
Figure 2 shows variations in hsCRP levels in the two
groups of study; hsCRP levels exhibited an almost con-
stant level after Setarud was administered and then de-
creased. However, in the control group an increasing
trend was observed before the 7th day. Treatment suc-
cessfully controlled increasing hsCRP levels (p = 0.02).
As shown in Figure 2, WBC and platelet counts in-
creased in both groups throughout the 7 days period,
indicating that treatment did not influence these two
markers (p = 0.71 and p = 0.13, respectively).
Patients in each group were divided into two groups of
NIHSS ≥ 15 and NIHSS < 15 based on NIHSS scores. La-
boratory findings in the IMOD™ group showed that only
hsCRP levels were significantly higher in patients with
NIHSS ≥ 15 at the time of referral (9.07 ± 1.75 vs. 21.92
± 5.38) and 4 days after the treatment was instituted
(10.95 ± 1.73 vs. 22.00 ± 4.69) (p = 0.01 and p = 0.02, re-
spectively). Evaluation of laboratory findings in the con-
trol group also revealed that only hsCRP levels were
significantly higher at the time of referral (9.84 ± 2.03 vs.
18.54 ± 96) and 4 days after the institution of treatment
(27.57 ± 3.98 vs. 16.05 ± 2.38) in patients with NIHSS ≥
15 (p = 0.04 and p = 0.04, respectively).
Figure 1 Changes in serum levels of TNF-α, IL-1, IL-6 and hsCRP in different days of study. Data are mean ± SE. Difference between two
groups is not significant for TNF-α (P = 0.10) and IL-1 (P = 0.20) but is significant for IL-6 (P = 0.04) and hsCRP (P = 0.02).
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treatment in each group, just the decrease of first day’s
serum IL6 level in comparison to 4th and 7th days’ serum
IL6 level in treatment group was significant (p = 0.023
and p = 0.049, respectively) and also treatment success-
fully controlled increasing hsCRP level.
Discussion
Inflammation is a pathological hallmark of ischemic
stroke and impairs outcome in patients via mechanisms
which are poorly understood [22]. Central nervous sys-
tem and the immune system interact in complex ways.
Neuron destruction due to cerebral ischemia induces an
immune response which is necessary to remove cell deb-
ris and initiate the regenerative process; however, thisinflammatory response can exacerbate cerebral damage,
resulting in secondary cerebral injuries [23,24]. Circula-
ting inflammatory mediators can activate cerebrovascu-
lar endothelium or glial cells in the brain and impact on
ischemic brain injury [22-25]. Cytokines are important
inflammatory mediators and it is well established that
both in vivo and in vitro ischemic challenges increase
the release of a large number of cytokines which are in-
volved in the necrosis of neuronal cells [26-29].
Among the large number of cytokines, TNF-α, IL-1
and IL-6, modulate tissue injury in experimental stroke
and are therefore potential targets in stroke therapy. The
effect of these cytokines on infarct evolution depends on
their availability in the ischemic penumbra in the early
phase after stroke onset [29]. Many neuroprotective
Figure 2 Changes in counts of Platelet (PLT) and White Blood Cells (WBC) in different days of study. Data are mean ± SE. Difference
between two groups is not significant for PLT (P = 0.13) and WBC (P = 0.71).
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have translated into clinical application. One reason for
this may be failure to consider clinical co-morbidities/risk
factors in experimental models [30].
Therefore, attempts are aimed at controlling the principle
inflammatory markers in acute ischemic stroke patients.
Several efforts are performed to design and undertake trials
of strategies that can modulate inflammation to improve
outcomes of ischemic stroke patients. Multiple studies has
been conducted to evaluate the effect of different medica-
tions on inflammation in AIS.
IL-1 is an established mediator of inflammation and
damage in central nervous system (CNS) diseases in ex-
perimental studies. The IL-1 family consists of three main
ligands: the agonists IL-1α and IL-1β, and the endogenous
antagonist, IL-1Ra [31]. Denes et al. demonstrated that
inhibition of IL-1 has beneficial effects on a variety of ex-
perimental paradigms of acute brain injury and is a prom-
ising clinical target in stroke. They proposed that blockade
of IL-1 could be therapeutically useful in several diseases
which are risk factors for stroke, and there is already con-
siderable pre-clinical and clinical evidence that inhibition
of IL-1 by IL-1 receptor antagonist may be valuable in the
management of acute stroke [32]. Pradillo et al., have
shown that a naturally occurring interleukin-1 receptor
antagonist (IL-1Ra) is protective against ischemic brain
damage in healthy animals. However, protective effects of
IL-1Ra have not been determined in comorbid animals
[30]. Shin et al. reported that the extent of complications
and disease severity decrease with suppression of TNF-α
and IL-1β [33].Vinychuk et al., tested IL-6 in serum of 109 patients
with ischemic stroke on the 1st day and 7 days after de-
veloping the disease. The decrease in concentration of
IL-6 on the 7th day was found after a complex therapy
with Flogensim in the study group in comparison with
the control group where a traditional therapy was used.
They found considerable difference in consequences of
the ischemic stroke in 21 days among patients pertaining
to different groups: the number of patients of the study
group, with better results, increased and number of the
patients of this group with no dynamic or even worsen-
ing in neurological status decreased [34].
De Aguilar-Nascimento et al. demonstrated enteral for-
mula containing whey protein may decrease inflammation
and increase antioxidant defenses in elderly patients with
ischemic stroke, compared to casein-containing formula
[35]. Montaner et al. in a pilot, double-blind, randomized,
multicenter clinical trial to study the efficacy of Simvastatin
in the acute phase of ischemic stroke, evaluated the evolu-
tion of several inflammation markers [IL-6, IL-8, IL-10,
monocyte chemoattractant protein-1, intercellular adhesion
molecule-1, vascular cell adhesion molecule-1, C-reactive
protein, sApo/Fas, tumor necrosis factor-alpha, E-selectin,
L-selectin and nitrites + nitrates] and neurological outcome
at baseline, day 1, 3, 5, 7 and 90. They found no differences
among the biomarkers studied regarding treatment alloca-
tion. But the outcome of their patients was improved [36].
Raju et al. performed a pilot randomized controlled trial
comparing the effect of colchicines (1 mg per day) with pla-
cebo on high sensitivity C-reactive protein (hsCRP) levels
and platelet function in 80 patients with acute coronary
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30 days. Their study provided no evidence that colchicine
suppresses inflammation in patients with acute coronary
syndrome or acute ischemic stroke [37].
IMOD™, which is a combination of plant extracts enriched
with selenium and has exhibited anti-inflammatory and im-
munoregulatory properties, has been studied in several trials
evaluating its effects on different clinical situations. In a
study by Mahmoodpoor et al., the effect of IMOD™ on
controlling signs and symptoms and treatment of patients
with sepsis was evaluated and it was reported that TNF-α
levels, as a chief inflammatory mediator involved in sepsis,
significantly decreased after treatment with IMOD™ com-
pared to the control group [11]. Another study by Eslami
et al. showed that Septimeb (IMOD™) had positive effects
on survival of patients with severe sepsis. Considering
withdrawal of Activated Protein C from market, IMOD™
might be considered as an adjuvant therapy for standard
treatment of sepsis [38]. In addition, Baghaee et al. evalu-
ated the effect of IMOD™ on inflammatory bowel disease
in rats and reported that the medication significantly de-
creased TNF-α and IL-1β levels, resulting in a decrease in
macroscopic tissue damage [12]. Also, the potential effects
of IMOD™ have been shown in initial evaluations in HIV
patients on decreasing TNF-α levels and decreasing TNF-
α and IL-2 levels during patenting processes [39]. These
studies showed that IMOD has anti-inflammatory effects.
In this context, IMOD™ as an immunomodulatory
medication may be a therapeutic option in AIS. Vafaee
et al. studied the neuroprotective effect of Setarud
(IMOD™) on cerebral ischemia in male rats. In this ran-
domized controlled animal study, rats intraperitoneally
administered with Setarud after Middle Cerebral Artery
occlusion. The study showed that Setarud could reduce
infarct volume of subjected rats. The medication could
alleviate degenerative changes in cortical neurons and
also improved motor function of rats with cerebral
ischemia [40].
In the present randomized clinical trial designed to
assess the effect of IMOD™ on main inflammatory bio-
markers, as reflexives of neuroinflammation in AIS, 99 pa-
tients with their first ischemic stroke attack were divided
into two groups of control and IMOD™ and evaluated in
relation to the levels of inflammatory markers in the first
days of symptom initiation. The results showed that
IMOD™ had a significant effect on some inflammatory
markers, such as IL-6 and hsCRP, which was consistent
with the clinical situation of patients in the case of hsCRP.
In addition, the medication decreased TNF-α and IL-1
levels, although with no statistical significance. Previous
studies have shown that IMOD™ can significantly reduce
TNF-α and IL-1 levels [11,12,39],but insignificant effect of
IMOD™ on these biomarkers in present study may be due
to different amount or source of secretion of variousbiomarkers in AIS; although, further studies measuring
biomarkers in serum and CSF may be needed to test this
hypothesis. This study shows that IMOD™ has immuno-
modulatory effects as shown in previous studies.
Several studies have shown that C-reactive protein
(CRP), an inflammatory marker, is associated with stroke
severity and outcome [41]. Dewan et al., demonstrated
that high CRP level is associated with stroke severity at
admission and is an independent predictor of early seven-
day mortality after ischemic stroke [42]. Hasan et al.
showed three biomarkers (C-reactive protein, P-selectin
and homocysteine) significantly differentiated between is-
chemic stroke and healthy control subjects [43]. Similarly,
in a study by Idicula et al., a significant relationship was
reported between a high CRP Level, a high NIHSS score
and high mortality rate [44]. Rajeshwar et al. showed that
hsCRP and NO levels predict the incidence of ischemic
stroke and hsCRP is an independent prognostic factor of
poor outcome at 3 months [45]. In the present study,
there was a significant relationship between disease sever-
ity (NIHSS)at referral and an increase in hsCRP level on
the first and the 4th days in both groups.
As in previous studies, we observed no major side effect
of IMOD injection except for few cases of superficial phle-
bitis that resolved by conservative measures. In a study by
Mahmoodpoor et al., it was shown that IMOD™ had no
side effects on coagulatory factors such as platelets, pro-
thrombin time, partial thromboplastin time, fibrinogen and
D-dimer [10]. In our study changes in WBC and platelet
counts subsequent to receiving IMOD™ were not signifi-
cant, so, present study supports the safety of the drug.
Limitation of the study
First, the number of included patients was small (limita-
tion of eligible patients in that period of time). Second, a
potential random error can’t be eliminated completely and
our results remained to be confirmed. Third, placebo was
not used in present study because of technical and ethical
limitations.
Conclusion
Considering the role of inflammation in the induction of
ischemic cerebral damage, it appears that treatment with
IMOD™ improves the profiles of main inflammatory
markers; therefore, it might be considered as a thera-
peutic option in ischemic strokes. However, it is neces-
sary to match laboratory findings with clinical findings
and follow them in the long term to further elucidate
such an effect. We recommend future multicenter stud-
ies with larger sample size and long duration period.
Evaluation of the effect of the drug on the inflammatory
profile in the cerebrospinal fluid (CSF) of experimental
models may provide more localizing data about the
effect of IMOD™.
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